Whitfield Dianne C.'s Form 4 filing
Tarsus Pharmaceuticals, Inc. (TARS) · filed Dec 1, 2023
- Accession no.
- 0001839516-23-000006
- Filed
- Dec 1, 2023
- Trade date
- Nov 29-30, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $136.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Whitfield Dianne C.CIK 0001839516 | Officer (Chief Human Resources Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | Common Stock | MOption exerciseAcquired | +23,920 | $0.00 | $0 | 35,139 | Direct | |
| Nov 30, 2023 | Common Stock | SSaleDisposed | −8,355 | $16.31 | −$136,270.05 | 26,784 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | Common Stock | MOption exerciseDisposed | −23,920 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Exhibit 24 - Power of Attorney